Результаты поиска

Сердечные биомаркеры для стратификации риска в недавно диагностированном миеломе высокого риска в пробе GMG-CONCEPT.

Сердечно-сосудистые неблагоприятные явления (CVAE) являются клиническими побочными эффектами во время лечения протеаозным ингибитором карфилзомиба. Мы изучили прогнозируемую ценность сердечных биомаркеров для начала CVAE у пациентов с недавно поставленным диагнозом множественной миэломы повышенного риска, обработанных изатуксимабом, карфиломибом, линалидомидом и дексаметазоном в исследовании GMG-CONCEPT (GMG-CONCEPT).NCT03104842). Пациенты, включенные в это перспективное, многоцентровое корреляционное исследование, имеют право на получение пробы сыворотки до начала лечения и на ≥ 1 позднее был

Совпадение в полном тексте источника
… The cardiotoxicity may thus not be comparable to the here investigated newly diagnosed MM population receiving first line treatment. … Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis. Leuk Lymphoma. 2018;59(11):2557–69. 11. Georgiopoulos G, Makris N, Laina A, Theodorakakou F, Briasoulis A, Trougakos IP, et al. …

Значительное сокращение числа пациентов с несколькими миломами с левой венерической венерической глобальной продольной траекторией: экспериментальный анализ случайной осведомленности.

Множественная миелома (ММ) - это злонамеренный вид, связанный с сердечно-сосудистыми осложнениями. Хотя эхокардиография играет ключевую роль в оценке сердечной функции, ее использование для последующей работы с пациентами, страдающими от болезней, носит ограниченный характер. Для этого описательного анализа мы приводим несколько рекомендуемых объективных показателей систолической функции левого желудочка (LV), пиковой глобальной продольной деформации (PGLS) и систолической функции правого желудочка (RV) 147 Пациенты MM на различных этапах лечения были направлены в нашу эхокардиографическую лаб

Совпадение в полном тексте источника
… Although cardiotoxicity associated with adriamycin was initially shown in the 1970s [ 22 ], the ongoing development of a whole host of novel targeted therapies has increased the number of agents that are now available and potentially cardiotoxic. … More importantly, this parameter should be used in clinical trials to ensure that cardiotoxicity risk is stratified by baseline PGL. …

Chemotherapy Side-Effects: Not All DNA Damage Is Equal.

Recent advances have increased survival rates of children and adults suffering from cancer thanks to effective anti-cancer therapy, such as chemotherapy. However, during treatment and later in life they are frequently confronted with the severe negative side-effects of their life-saving treatment. The occurrence of numerous features of accelerated aging, seriously affecting quality of life, has now become one of the most pressing problems associated with (pediatric) cancer treatment. Chemotherapies frequently target and damage the DNA, causing mutations or genome instability, a major hallmark

Совпадение в полном тексте источника
… Cardiotoxicity of Chemotherapeutic Agents Drug Saf. 2000 22 263 302 10.2165/00002018-200022040-00002 10789823 52. Yeh E.T. Cardiotoxicity induced by chemotherapy and antibody therapy Annu. Rev. Med. 2006 57 485 498 10.1146/annurev.med.57.121304.131240 16409162 53. Simbre V.C. Duffy S.A. … Cardiotoxicity of Cancer Chemotherapy Pediatr. Drugs 2005 7 187 202 10.2165/00148581-200507030-00005 15977964 54. Madeddu C. Deidda M. Piras A. Cadeddu C. Demurtas L. Puzzoni M. Piscopo G. Scartozzi M. Mercuro G. Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy J. …

Case Report: AL Amyloidosis Severe Restrictive Cardiomyopathy Associated With Multiple Myeloma-Diagnostic Difficulties.

BackgroundCardiac AL amyloidosis as a complication of multiple myeloma (MM) is a formidable life-threatening condition. The first-line therapy for both MM and systemic AL amyloidosis is proteasome inhibitors (PIs). Unfortunately, the use of PIs may lead to cardiovascular toxicity development, which requires specific cardio-oncology supervision.Case reportA 57-year-old woman was admitted to a university hospital with clinical manifestation of progressive chronic heart failure. The patient had hypertension and no history of diabetes mellitus, myocardial infarction (MI), stroke, and arrhythmias.

mHealth technologies in research studying cardiovascular health in cancer: A systematic review.

Cancer survivors face an increased risk of cardiovascular disease (CVD) due to treatment-related toxicity, lifestyle factors, and comorbidities. Addressing CV health is crucial for improving quality of life and long-term outcomes. The American Heart Association's Life's Essential 8 framework highlights modifiable determinants of CV health, emphasizing early detection and monitoring. Mobile health (mHealth) technologies, such as wearables and smartphone apps, offer continuous tracking, yet their applications in cancer survivorship remain unclear. This review systematically characterizes the typ

Совпадение в полном тексте источника
… Recognizing and managing cardiotoxicity from across the cancer continuum (diagnosis, treatment, remission) is complex due to these varied risk factors, which can lead to severe complications. … Evidence suggests that poor sleep is associated with higher CV risk [ 54 ], which also may compound the cardiotoxic effects of cancer treatments. …

A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma.

BackgroundCarfilzomib is a second-generation proteasome inhibitor (PI) used for combination therapy with dexamethasone and/or lenalidomide in patients with relapsed or refractory multiple myeloma. Reports indicate that PIs have a unique toxicity profile that includes thrombocytopenia as a hematologic adverse event; however, its occurrence has not yet been quantified systematically.ObjectivesThe main objective of our systematic review and meta-analysis is to investigate the incidence of thrombocytopenia in patients with multiple myeloma after treatment with carfilzomib.DesignSelection of studie

Совпадение в полном тексте источника
… The second meta-analysis, with data from 4164 patients and 29 clinical trials, also confirmed that carfilzomib significantly increases the risk of cardiotoxicity. … Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis . Leuk Lymphoma 2018 ; 59 ( 11 ): 2557 – 2569 . 29465266 10.1080/10428194.2018.1437269 …

Liposomal Drug Delivery Systems and Anticancer Drugs.

Cancer is a life-threatening disease contributing to ~3.4 million deaths worldwide. There are various causes of cancer, such as smoking, being overweight or obese, intake of processed meat, radiation, family history, stress, environmental factors, and chance. The first-line treatment of cancer is the surgical removal of solid tumours, radiation therapy, and chemotherapy. The systemic administration of the free drug is considered to be the main clinical failure of chemotherapy in cancer treatment, as limited drug concentration reaches the tumour site. Most of the active pharmaceutical ingredien

Совпадение в полном тексте источника
… However, its clinical uses are limited by considerable cardiotoxicity and cytotoxicity. … In another related study, it was reported that DaunoXome® displayed a favorable cardiac toxicity profile, also allowing an increased anthracycline dose without increasing cardiotoxicity [ 108 ]. …

Cardiovascular Considerations in Patients Undergoing Hematopoietic Cell Transplantation.

Opinion statementCardiac dysfunction is a serious adverse effect of cancer therapies that can interfere with quality of life and impact long-term survival in patients with cancer. Hematopoietic cell transplantation is a potentially curative therapy for many advanced hematologic malignancies and bone marrow failure syndromes, however is associated with several short- and long-term adverse effects, including importantly, cardiovascular toxicities. The goal of this review article is to describe the cardiovascular events that may develop before, during, and after hematopoietic cell transplantation

Совпадение в полном тексте источника
… Historically, Cy-related acute cardiotoxicity, which includes endothelial injury, arrhythmias, and heart failure, often occurs within 10 days of administration. … Additional data is needed to further understand the potential increased cardiotoxicity with PT-Cy but underscores the importance of careful monitoring with PT-Cy in higher-risk patients. …

Post-Transplant Cyclophosphamide for the Prevention of Graft-vs.-Host Disease in Allogeneic Hematopoietic Cell Transplantation: A Guide to Management for the Advanced Practitioner.

Cyclophosphamide remains a critical component to haploidentical transplant conditioning regimens. Post-transplant cyclophosphamide (PTCy) emerged as an effective component of graft-vs.-host disease (GVHD) prophylaxis in the nonmyeloablative haploidentical bone marrow transplant setting. The relative ease of administration compared with ex vivo manipulations and efficacy in reducing GVHD has led to increasing PTCy use in transplant centers around the world. The role of PTCy has expanded to haploidentical transplantation with myeloablative conditioning regimens and peripheral blood progenitor ce

Совпадение в полном тексте источника
… TOXICITY AND MANAGEMENT CONSIDERATIONS FOR THE ADVANCED PRACTITIONER Cardiotoxicity Cyclophosphamide-induced cardiotoxicity (CIC) is a dose-limiting toxicity reported after administration of high doses. … A small retrospective report suggests that the risk of cardiotoxicity might be increased with PTCy ( Souchet et al., 2013 ). …

Cardiac Monitoring for Patients Undergoing Treatment With MEK Inhibitor Monotherapy.

PURPOSE OF REVIEW: Aberrant activation of the RAS-RAF-MEK-ERK signaling pathway contributes to numerous malignancies, congenital syndromes, and cardiovascular disorders, establishing MEK inhibitors (MEKi) as crucial therapeutic agents. MEKi demonstrate substantial clinical benefit as monotherapy (e.g., NF1-associated tumors) or combination therapy (e.g., melanoma, glioma, congenital RASopathies). Cardiovascular adverse events, primarily asymptomatic reductions in left ventricular ejection fraction (LVEF), have prompted intensive echocardiographic monitoring. RECENT FINDINGS: Emerging evidence

Совпадение в полном тексте источника
… Permissive cardiotoxicity acknowledges the importance of both the expected endpoint of a patient’s disease and the acceptable limits of reversible or permanent cardiac decline. … These markers signal early myocardial stress or injury and have proven useful in detecting cardiotoxicity in patients receiving anthracyclines and immune checkpoint inhibitors (ICIs). …

Drug-induced oxidative stress in cancer treatments: Angel or devil?

Oxidative stress (OS), defined as redox imbalance in favor of oxidant burden, is one of the most significant biological events in cancer progression. Cancer cells generally represent a higher oxidant level, which suggests a dual therapeutic strategy by regulating redox status (i.e., pro-oxidant therapy and/or antioxidant therapy). Indeed, pro-oxidant therapy exhibits a great anti-cancer capability, attributing to a higher oxidant accumulation within cancer cells, whereas antioxidant therapy to restore redox homeostasis has been claimed to fail in several clinical practices. Targeting the redox

Совпадение в полном тексте источника
… Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res. Treat. 2021;188:21–36. doi: 10.1007/s10549-021-06280-x. 134. Klein I., Lehmann H.C. … Metabolic aspects of anthracycline cardiotoxicity. Curr. Treat. Options Oncol. 2021;22:18. doi: 10.1007/s11864-020-00812-1. 144. Wu L., Wang L., Du Y., Zhang Y., Ren J. Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity. Trends Pharmacol. …

Острая сердечная недостаточность у пациентов, страдающих гематологическими заболеваниями: общенациональный анализ 2016-2021.

ИСТОРИЯ ВОПРОСА: Острая сердечная недостаточность ~9% пациентов с гематологическими отклонениями. Цель этого исследования заключалась в оценке воздействия острой сердечной недостаточности на внутрибольничную смертность среди пациентов с гематологическими заболеваниями и в выявлении независимых прогнозов смертности среди этой группы населения. МЕТОДЫ: Национальная стационарная выборка2016-2021) был задан вопрос о взрослых (см.⩾18 возраст) с гематологическими отклонениями и смертностью в больницах. Среди них мы обнаружили пациентов, которые были госпитализированы с диагнозом острой сердечной нед

Совпадение в полном тексте источника
… Introduction Hematological malignancies (HMs) represent 3.3% of cancer incidence in the United States and carry a 3.8% mortality. 1 These patients often show increased cardiac remodeling and dysfunction, due to the inflammatory and fibrotic effects of clonal hematopoiesis and direct cardiotoxicity of … HSCT and the usage of cardiotoxic agents such as anthracyclines, proteasome inhibitors, and tyrosine kinase inhibitors (TKIs) are common in this population. …

Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities.

The use of chimeric antigen receptor T (CAR-T) cells is a significant therapeutic improvement increasing the prognosis for patients with a variety of hematological malignancies. However, this therapy has also sometimes life-threatening, complications. Therefore, knowledge of the treatment and management of these complications, especially in treatment centers and intensive care units, respectively, is of outstanding importance. This review provides recommendations for the diagnosis, management, and treatment of CAR-T cell-associated complications such as cytokine release syndrome, immune effect

Совпадение в полном тексте источника
… Cardiotoxicity Cardiotoxicity is recognized as an organ-specific side effect following CAR-T cell therapy, occurring in 10 to 36% of cases [ 69 ]. … Ganatra S Dani SS Yang EH Zaha VG Nohria A Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer JACC CardioOncol 2022 4 5 616 623 10.1016/j.jaccao.2022.07.014 36636447 PMC9830211 Ganatra S, Dani SS, Yang EH, Zaha VG, Nohria A (2022) Cardiotoxicity of T-Cell Antineoplastic Therapies …

What the Intensivists Need to Know About Critically Ill Myeloma Patients

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Among them, carfilzomib has shown the highest rates of cardiotoxicity. In a meta-analysis looking at the cardiotoxicity of carfilzomib, all-grade and high-grade cardiotoxicity were seen in 18% and 8% of patients, respectively, higher than the control arm. … The first intervention in suspected cardiotoxicity is to hold further therapy and follow expectant management. …

Clinical outcomes of chemotherapy in cancer patients with different ethnicities.

BackgroundChoosing the most effective chemotherapeutic agent with safest side effect profile is a common challenge in cancer treatment. Although there are standardized chemotherapy protocols in place, protocol changes made after extensive clinical trials demonstrate significant improvement in the efficacy and tolerability of certain drugs. The pharmacokinetics, pharmacodynamics, and tolerance of anti-cancer medications are all highly individualized. A driving force behind these differences lies within a person's genetic makeup.Recent findingsPharmacogenomics, the study of how an individual's g

Совпадение в полном тексте источника
… Changes in CBR activity due to polymorphisms within CBR genes can have increased risk of anthracycline‐related cardiotoxicity. … Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the pediatric oncology group experience. J Clin Oncol. 1997;15(4):1544‐1552. 94. Hasan S, Dinh K, Lombardo F, Kark J. Doxorubicin cardiotoxicity in African Americans. J Natl Med Assoc. 2004;96(2):196‐199. 95. …

Brazilian Position Statement on the Use Of Multimodality Imaging in Cardio-Oncology - 2021.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions.

Chimeric antigen receptor (CAR)-T cell therapy is effective in the treatment of refractory/relapsed (r/r) hematological malignancies (r/r B-cell lymphoblastic leukemia, B-cell lymphoma, and multiple myeloma). In addition, it is being explored as a treatment option for solid tumors. As of 31 March 2022, seven CAR-T therapies for hematological malignancies have been approved worldwide. Although CAR-T therapy is an effective treatment for many malignancies, it also causes adverse effects. The incidence of cytokine release syndrome (CRS), the most common adverse reaction after infusion of CAR-T ce

Совпадение в полном тексте источника
… Cardiotoxicity occurs between 2 and 24 days after CAR-T cell infusion ( Ganatra et al., 2020 ; Lefebvre et al., 2020 ). … Pathan et al. (2011) found that IL-6 (serum endothelial activating cytokine) inhibits the contractile function of myocardium through the p38MAPK signaling pathway; 3 ) Increased expression of TNF-α in the myocardium enhances cardiotoxicity ( Michel et al., 2022 ); 4 ) Direct cardiotoxicity caused by …

Long-Term Cardiovascular Outcomes in Childhood Cancer Survivors: A Systematic Review.

In recent years, childhood cancer appears to have become more common. Cardiovascular (CV) diseases have been cited as the leading cause of noncancer mortality among childhood cancer survivors. This systematic review evaluated the long-term CV outcomes of childhood cancer survivors. Eleven studies, published between 2015 and 2024 that satisfied the criteria for a thorough assessment, are included in the study. The research found consistent associations between specific cancer treatments, such as anthracyclines, radiation therapy, and total body irradiation, and increased risks of cardiomyopathy

Совпадение в полном тексте источника
… For example, several echocardiography investigations have shown that some childhood cancer survivors experience subclinical cardiotoxicity, which may evolve to heart failure over time [ 6 ]. … The major risks associated with this disease include cardiotoxic therapies, conditioning programs, and post-transplant problems. …

In vitro models of breast cancer bone metastasis: analyzing drug resistance through the lens of the microenvironment.

Even though breast cancers usually have a good outcome compared to other tumors, the cancer can progress and create metastases in different parts of the organism, the bone being a predilection locus. These metastases are usually the cause of death, as they are mostly resistant to treatments. This resistance can be caused by intrinsic properties of the tumor, such as its heterogeneity, but it can also be due to the protective role of the microenvironment. By activating signaling pathways protecting cancer cells when exposed to chemotherapy, contributing to their ability to reach dormancy, or ev

Cardiometabolic Comorbidities in Cancer Survivors: JACC: CardioOncology State-of-the-Art Review.

There are nearly 17 million cancer survivors in the United States, including those who are currently receiving cancer therapy with curative intent and expected to be long-term survivors, as well as those with chronic cancers such as metastatic disease or chronic lymphocytic leukemia, who will receive cancer therapy for many years. Current clinical practice guidelines focus on lifestyle interventions, such as exercise and healthy eating habits, but generally do not address management strategies for clinicians or strategies to increase adherence to medications. We discuss 3 cardiometabolic comor

Совпадение в полном тексте источника
… Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients. Clin Breast Cancer. 2017;17(1):11–17. doi: 10.1016/j.clbc.2016.07.003. 159. Willmot M., Gibson C., Gray L., Murphy S., Bath P. … Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies. Cancer Treat Rev. 2017;59:123–131. doi: 10.1016/j.ctrv.2017.07.006. …